Memory Pharmaceuticals 8-K 2008
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Memory Pharmaceuticals Corp.
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On December 3, 2008, Memory Pharmaceuticals (the "Registrant") received notification from the NASDAQ Listing Qualifications Panel (the "Panel") that the Panel has determined to delist the Company’s securities from The NASDAQ Capital Market. However, on the same day, the Registrant was notified that the NASDAQ Listing and Hearing Review Council (the "Review Council") had called for review the Panel’s December 3, 2008 decision and had determined to stay the Panel’s decision pending further action by the Review Council. As a result, the Registrant’s securities will continue to trade on The NASDAQ Capital Market pending further consideration of this matter by the Review Council. A copy of the press release that includes this announcement is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
99.1 Press Release dated December 3, 2008
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.